Federal Register Notice: FDA’s Blood Products Advisory Committee will meet 9/29, from 8 a.m. to 5 p.m. at the FDA Conference Room 1066, 5630 Fishers Lane, Rockville, MD. The committee will discuss Novartis Pharmaceutical Corp.’s NDA for Exjade (deferasirox) tablets for oral suspension proposed for treating chronic iron overload due to blood transfusions (transfusional hemosiderosis). The committee will also hear an overview of the research programs in the Laboratory of Hemostasis and the Laboratory of Plasma Derivatives, in CBER’s Division of Hematology, Office of Blood Research and Review. Contact Donald W. Jehn or Pearline K. Muckelvene, (301) 827-0314. To view this notice, click here.